About Affimed NV (NASDAQ:AFMD)
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AFMD
- CUSIP: N/A
- Web: www.affimed.com/
- Market Cap: $94.47 million
- Outstanding Shares: 43,938,000
- 50 Day Moving Avg: $2.16
- 200 Day Moving Avg: $2.19
- 52 Week Range: $1.65 - $2.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.69
- P/E Growth: 0.00
- Annual Revenue: $3.99 million
- Price / Sales: 23.68
- Book Value: $1.10 per share
- Price / Book: 1.95
- EBITDA: ($36,260,000.00)
- Net Margins: -1,564.37%
- Return on Equity: -72.67%
- Return on Assets: -57.82%
- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 6.69%
- Quick Ratio: 6.65%
- Average Volume: 252,318 shs.
- Beta: 3.65
- Short Ratio: 2.6
Frequently Asked Questions for Affimed NV (NASDAQ:AFMD)
What is Affimed NV's stock symbol?
Affimed NV trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed NV's earnings last quarter?
Affimed NV (NASDAQ:AFMD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. The firm earned $0.51 million during the quarter, compared to analysts' expectations of $1.31 million. Affimed NV had a negative return on equity of 72.67% and a negative net margin of 1,564.37%. The company's revenue was down 75.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. View Affimed NV's Earnings History.
When will Affimed NV make its next earnings announcement?
Where is Affimed NV's stock going? Where will Affimed NV's stock price be in 2017?
4 analysts have issued 1 year price targets for Affimed NV's shares. Their forecasts range from $2.00 to $10.00. On average, they expect Affimed NV's stock price to reach $5.38 in the next year. View Analyst Ratings for Affimed NV.
Are investors shorting Affimed NV?
Affimed NV saw a decrease in short interest in September. As of September 29th, there was short interest totalling 409,062 shares, a decrease of 42.6% from the September 15th total of 712,056 shares. Based on an average daily volume of 386,134 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.5% of the company's shares are sold short.
Who are some of Affimed NV's key competitors?
Some companies that are related to Affimed NV include Ovid Therapeutc (OVID), Recro Pharma (REPH), Fate Therapeutics (FATE), Summit Therapeutics PLC (SMMT), Vascular Biogenics (VBLT), Synthetic Biologics (SYN), Cempra (CEMP), Dimension Therapeutics (DMTX), Adverum Biotechnologies (ADVM), Conatus Pharmaceuticals (CNAT), Redhill Biopharma (RDHL), Verastem (VSTM), XBiotech (XBIT), Agile Therapeutics (AGRX), Immune Design Corp. (IMDZ), Cellular Biomedicine Group (CBMG), Verona Pharma Plc (VRP) and ImmuPharma PLC (IMM).
How do I buy Affimed NV stock?
Shares of Affimed NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed NV's stock price today?
MarketBeat Community Rating for Affimed NV (NASDAQ AFMD)MarketBeat's community ratings are surveys of what our community members think about Affimed NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Affimed NV stock can currently be purchased for approximately $2.15.
Consensus Ratings for Affimed NV (NASDAQ:AFMD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$5.38 (150.00% upside)|Consensus Price Target History for Affimed NV (NASDAQ:AFMD)
Analysts' Ratings History for Affimed NV (NASDAQ:AFMD)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/27/2017||Jefferies Group LLC||Reiterated Rating||Hold||$2.50||Low|
|7/13/2017||SunTrust Banks, Inc.||Initiated Coverage||Buy -> Buy||$7.00||High|
|5/18/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$10.00||Low|
|11/3/2016||Leerink Swann||Reiterated Rating||Hold||$2.00||N/A|
|5/18/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
|4/11/2016||BMO Capital Markets||Initiated Coverage||Outperform||$7.00||N/A|
Earnings History for Affimed NV (NASDAQ:AFMD)Earnings History by Quarter for Affimed NV (NASDAQ AFMD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/1/2017|| || || || || || || || |
|8/3/2017||6/30/2017||($0.22)||($0.20)||$1.31 million||$0.51 million||View||Listen|
|5/17/2017||3/31/2017||($0.24)||($0.21)||$1.73 million||$1.94 million||View||N/A|
|3/30/2017||12/31/2016||($0.31)||($0.17)||$1.20 million||$1.37 million||View||N/A|
|11/2/2016||Q316||($0.26)||($0.31)||$2.65 million||$0.94 million||View||N/A|
|8/10/2016||Q216||($0.22)||($0.24)||$2.10 million||$2.07 million||View||Listen|
|5/18/2016||Q116||($0.15)||($0.25)||$1.88 million||$1.90 million||View||Listen|
|3/30/2016||Q415||($0.18)||($0.19)||$1.71 million||$1.66 million||View||Listen|
|11/10/2015||Q315||($0.25)||($0.27)||$1.87 million||$1.20 million||View||Listen|
|8/4/2015||Q215||($0.14)||($0.21)||$2.56 million||$2.21 million||View||N/A|
|5/21/2015||Q115||($0.14)||($0.07)||$4.75 million||$2.82 million||View||Listen|
|3/25/2015||Q414||($0.39)||($0.24)||$0.89 million||$0.09 million||View||N/A|
|11/18/2014||Q314||($0.33)||$2.69||$0.89 million||$2.35 million||View||N/A|
Earnings Estimates for Affimed NV (NASDAQ:AFMD)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Affimed NV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Affimed NV (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Affimed NV (NASDAQ:AFMD)
Latest Headlines for Affimed NV (NASDAQ:AFMD)
Loading headlines, please wait.
Affimed NV (AFMD) Chart for Saturday, October, 21, 2017